ReviewRetrovirology2005
Molecular strategies to inhibit HIV-1 replication.
Review in Retrovirology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Production and Purification of Lentiviral Vectors.Methods in molecular biology (Clifton, N.J.) · 2026Article
- HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence.Health science reports · 2024Article
- Inhibition of HIV-1 replication using the CRISPR/cas9-no NLS system as a prophylactic strategy.Heliyon · 2022Article
- Dendrimeric HIV-peptide delivery nanosystem affects lipid membranes structure.Scientific reports · 2021Article
- Marine Algal Antioxidants as Potential Vectors for Controlling Viral Diseases.Antioxidants (Basel, Switzerland) · 2020Article
- New drugs are not enough‑drug repositioning in oncology: An update.International journal of oncology · 2020Review
- Targeting HIV-1 proviral transcription.Current opinion in virology · 2019Review
- Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy.Molecules (Basel, Switzerland) · 2018Review
- Genetic manipulation of specific neural circuits by use of a viral vector system.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Nanostructures for the Inhibition of Viral Infections.Molecules (Basel, Switzerland) · 2015Review
- Reduction of HIV-1 infectivity through endoplasmic reticulum-associated degradation-mediated Env depletion.Journal of virology · 2015Article
- Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages.Journal of neuroinflammation · 2014Article
- Targeting strategies for delivery of anti-HIV drugs.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Article
- Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2012Review
- Enhanced inhibition of Avian leukosis virus subgroup J replication by multi-target miRNAs.Virology journal · 2011Article
- Thermodynamic profiling of HIV RREIIB RNA-zinc finger interactions.Journal of molecular biology · 2009Article
- World AIDS Day 2007: AIDS at 26, are we there yet?Retrovirology · 2007Article
- Optimal design and validation of antiviral siRNA for targeting HIV-1.Retrovirology · 2007Article
- Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites.Retrovirology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human immunodeficiency virus type 1 (HIV-1) is the primary cause of the acquired immunodeficiency syndrome (AIDS), which is a slow, progressive and degenerative disease of the human immune system. The pathogenesis of HIV-1 is complex and characterized by the interplay of both viral and host factors. An intense global research effort into understanding the individual steps of the viral replication cycle and the dynamics during an infection has inspired researchers in the development of a wide spectrum of antiviral strategies. Practically every stage in the viral life cycle and every viral gene product is a potential target. In addition, several strategies are targeting host proteins that play an essential role in the viral life cycle. This review summarizes the main genetic approaches taken in such antiviral strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.